UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000037505 |
|---|---|
| Receipt number | R000042740 |
| Scientific Title | Validation study of the prognostic and predictive value of TP53 signature for breast cancer |
| Date of disclosure of the study information | 2019/09/18 |
| Last modified on | 2021/07/27 14:16:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Validation study of the prognostic and predictive value of TP53 signature for breast cancer
Acronym
Validation study of the prognostic and predictive value of TP53 signature for breast cancer
Scientific Title
Validation study of the prognostic and predictive value of TP53 signature for breast cancer
Scientific Title:Acronym
Validation study of the prognostic and predictive value of TP53 signature for breast cancer
Region
| Japan |
Condition
Condition
Breast Cancer
Classification by specialty
| Hematology and clinical oncology | Breast surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to validate whether the TP53 status diagnosed by the TP53 signature diagnostic kit can predict the prognosis and the therapeutic effect of neoadjuvant chemotherapy in breast cancer patients.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Pathological complete response rate
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Female
Key inclusion criteria
The subjects are the patients enrolled in the following five clinical trials conducted by JBCRG and OOTR.
i. JBCRG-01 (n=202)
ii. JBCRG-02 (n=31)
iii. JBCRG-02' (n=19)
iv. JBCRG-03 (n=130)
v. OOTR-N003 (n=500)
In addition, perioperative chemotherapy-free hormone receptor positive breast cancer (HR+BC) patients will be collected targeting at 340 cases.
Selection criteria for perioperative chemotherapy-free HR+BC cases are as follows according to the eligibility criteria of the above five clinical trials.
Cases that satisfy all the following 1 to 7
1. Cases with histologically confirmed primary breast cancer (invasive cancer) and undergone curative resection
2. Cases in which TNM at diagnosis satisfies the following {cT1 c-3 cN0 cM0 (> 1 cm) / cT1-3 cN1 cM0}
3. Cases in which chemotherapy were not given as preoperative or postoperative adjuvant therapy (cases in which endocrine therapy were given are acceptable)
4. 20 years old or older and less than 70 years old
5. Cases in which regular follow-up has been performed at the facility where surgery for breast cancer was performed and of whom sufficient prognostic information can be obtained (Follow-up period must be over 5 years in cases without recurrence).
6. Cases in which the following samples can be submitted
Cases with preoperative endocrine therapy: Biopsy tumor samples obtained before endocrine therapy (formalin fixed paraffin embedded tissue, total of 12 slides of 4 micro meter thick unstained specimens)
Cases without preoperative endocrine therapy: Biopsy tumor samples at diagnosis or tumor samples resected by surgery (formalin fixed paraffin embedded tissue, total of 12 slides of 4 micro meter thick unstained specimens)
7. Cases diagnosed with primary breast cancer between August 2005 and July 2009
The number of cases in each facility is limited to 60 cases, and all eligible cases after August 2005 have to be registered consecutively.
Key exclusion criteria
1. Male
2. Cases judged by investigator to be unfit to be enrolled into the study
Target sample size
840
Research contact person
Name of lead principal investigator
| 1st name | Chikashi |
| Middle name | |
| Last name | Ishioka |
Organization
Institute of Development, Aging and Cancer, Tohoku University
Division name
Department of Clinical Oncology
Zip code
980-8575
Address
4-1, Seiryo-machi, Aobaku, Sendai, Miyagi, Japan
TEL
022-717-8543
chikashi@tohoku.ac.jp
Public contact
Name of contact person
| 1st name | Shin |
| Middle name | |
| Last name | Takahashi |
Organization
Institute of Development, Aging and Cancer, Tohoku University
Division name
Department of Clinical Oncology
Zip code
980-8575
Address
4-1, Seiryo-machi, Aobaku, Sendai, Miyagi, Japan
TEL
022-717-8543
Homepage URL
shin.takahashi.e7@tohoku.ac.jp
Sponsor or person
Institute
Japan Agency for Medical Research and Development
Institute
Department
Personal name
Funding Source
Organization
Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Tohoku University Hospital Research Ethics Committee
Address
1-1, Seiryo-machi, Aobaku, Sendai, Miyagi, Japan
Tel
022-728-4105
ec@rinri.hosp.tohoku.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 09 | Month | 18 | Day |
Related information
URL releasing protocol
Publication of results
Partially published
Result
URL related to results and publications
Number of participants that the trial has enrolled
800
Results
A total of 800 specimens were collected from 23 sites in Japan, and TP53 signature data were obtained for a total of 753 cases, excluding insufficient specimen cases (wild-type (wt) 361 cases and mutant (mt) 392 cases).In a preoperative chemotherapy cohort, the pCR ratio in the mt group was significantly higher than that of wt group (the estimate of the common odds ratio of the mt group for the wt group: 5.599, 95% CI: 1.876-16.705, p=0.0008).
Results date posted
| 2021 | Year | 07 | Month | 27 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2019 | Year | 09 | Month | 10 | Day |
Date of IRB
| 2019 | Year | 09 | Month | 26 | Day |
Anticipated trial start date
| 2019 | Year | 09 | Month | 26 | Day |
Last follow-up date
| 2021 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2021 | Year | 03 | Month | 31 | Day |
Date trial data considered complete
| 2021 | Year | 03 | Month | 31 | Day |
Date analysis concluded
| 2021 | Year | 03 | Month | 31 | Day |
Other
Other related information
We verify that the pCR ratio in patients diagnosed with mt by TP53 signature is higher than that in patients diagnosed with wt in patients treated with preoperative chemotherapy.
To match the patients background between TP53 signature status, we use propensity score (PS) estimated by logistic regression analysis. The covariates are ER, PgR, Ki67, age, menopausal status, tumor diameter, lymph node status and vascular invasion. We divide patients into 3 groups by PS so that the number of patients in the stratum is equal. The pCR ratio, the 95% confidence interval by the Cloper-Pearson method and the odds ratio are calculated in the patients with mt and wt by TP53 signature, respectively. In addition, the null hypothesis that the common odds ratio is 1 is tested at a two-sided significance level of 5% using the Mantel-Haenszel test.
Management information
Registered date
| 2019 | Year | 07 | Month | 26 | Day |
Last modified on
| 2021 | Year | 07 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042740
